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ORIGINAL ARTICLEEvaluation of visual triage for screening of Middle East respiratory
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INSERM U1095, Marseille, FranceAbstractThe emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in September 2012 in Saudi Arabia had attracted the attention
of the global health community. In 2017 the Saudi Ministry of Health released a visual triage system with scoring to alert healthcare workers in
emergency departments (EDs) and haemodialysis units for the possibility of occurrence of MERS-CoV infection. We performed a
retrospective analysis of this visual score to determine its sensitivity and specificity. The study included all cases from 2014 to 2017 in a
MERS-CoV referral centre in Riyadh, Saudi Arabia. During the study period there were a total of 2435 suspected MERS cases. Of these,
1823 (75%) tested negative and the remaining 25% tested positive for MERS-CoV by PCR assay. The application of the visual triage score
found a similar percentage of MERS-CoV and non–MERS-CoV patients, with each score from 0 to 11. The percentage of patients with a
cutoff score of 4 was 75% in patients with MERS-CoV infection and 85% in patients without MERS-CoV infection (p 0.0001). The
sensitivity and specificity of this cutoff score for MERS-CoV infection were 74.1% and 18.6%, respectively. The sensitivity and specificity
of the scoring system were low, and further refinement of the score is needed for better prediction of MERS-CoV infection.
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E-mail: zmemish@yahoo.comIntroductionThe first case of Middle East respiratory syndrome coronavirus
(MERS-CoV) was described in 2012 from a hospitalized patient
in a private hospital in the Kingdom of Saudi Arabia [1]. The
disease has attracted the attention of the global heathThis is an open access articommunity because it carries a high fatality rate of 40% to 60%
[2–5]. The high case fatality rate could be an overestimate
because the exact numbers of asymptomatic and mild cases
were not well defined. Recent estimates indicate an overall
fatality rate of 35%. Over the 4 years since the virus’s discov-
ery, there have been multiple healthcare-associated outbreaks
[2,3,6–15]. The main reason for these outbreaks was the dif-
ficulties in early identification of MERS-CoV confirmed cases
from influenza-like illness cases, leading to inappropriate
application of infection control standards and quarantine. In an
effort to facilitate this task, differentiation between MERS-CoV
and non–MERS-CoV cases based on epidemiologic and clinical
indicators was evaluated in few studies, but with no helpful
findings [16–18]. A case–control analysis identified someNew Microbe and New Infect 2018; 26: 49–52
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analysis [16]. In other studies, presenting symptoms were not
specific for MERS-CoV infection [17,18].
The Saudi Ministry of Health (MoH) developed and released
a visual triage system to be used by all hospitals for the early
identification of patients with acute respiratory illness in EDs,
dialysis units and clinics [19]. In this study, we retrospectively
evaluated the performance of this visual acute respiratory
illness triage system for the prediction of MERS-CoV infection.Patients and methodsPrince Mohammed bin Abdulaziz Hospital is a referral centre for
MERS-CoV patients diagnosed in the central region based in
Riyadh, Saudi Arabia. The visual triage form documents the
institution, unit, healthcare worker involved in the triage with
name and signature, and patient contact details (Fig. 1). It com-
prises nine items classified into two sections, with one related to
the patient’s symptoms and signs and presentation and the other
section related to the patient’s potential risk of exposure to
MERS-CoV, each with a defined predetermined score (Fig. 1).
The patient’s symptoms include fever, cough, shortness of
breath, nausea, vomiting or diarrhea, sore throat or runny nose
and the presence of underlying conditions including diabetes
mellitus, chronic renal failure, coronary artery disease or heart
failure. Any patient scoring4will need isolation and assessment
by a physician before ruling out MERS-CoV. All admitted patients
from 1 April 2014 to December 2017 who were tested for
MERS-CoV were included in this study. MERS-CoV testing was
done using nasopharyngeal swabs as described previously [4].
MERS-CoV diagnosis was based on positive real-time reverse-
transcriptase PCR as described previously [4,16,20].
We calculated the triage score for each patient on the basis
of the scores from Saudi MoH [19] using the identified signs and© 2018 The Author(s). Published by Elsevier Ltd, NMNI, 26, 49–52
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was calculated and compared between those with and without
MERS-CoV infection using a chi-square test.
We then calculated the sensitivity and specificity of the
scoring scale adopted for the identification of positive cases in
relation to virus detection by real-time PCR. Sensitivity and
specificity were calculated, for an original cutoff value of 4. We
subsequently challenged the triage scoring by increasing the
values of MERS-CoV potential exposure specific items 7 to 9 by
giving 6 points for factor 7 instead of 3, 4 points for factor 8
instead of 2 and 2 for factor 9 instead of 1. We then calculated
sensitivity and specificity in the same manner.ResultsDuring the study period from 2014 to 2017, there was a total of
2435 suspected MERS-CoV cases. Of these, 1823 cases (75%)
tested negative and the remaining 25% tested positive for
MERS-CoV by PCR. The application of the visual triage score
resulted in a similar percentage of MERS-CoV and non–MERS-
CoV patients with each score from 0 to 11 (Fig. 2). The per-
centage of patients with a cutoff score of 4 was 75% in pa-
tients with MERS and 85% in patients without MERS (p 0.0001).
The sensitivity and specificity of this cutoff score for MERS-CoV
infection were 74.1% and 18.6%, respectively. Increasing the
values of items 7 to 9 and recalculating the score, as indicated
above, was not discriminative as well.DiscussionWe retrospectively evaluated the proposed Saudi MoH triage
scoring system for the screening of MERS-CoV patients. During
the outbreak of severe acute respiratory syndrome, oneFIG. 1. Visual triage form showing two
sections, one related to patient present-
ing symptoms and signs and one related
to risk of exposure to MERS-CoV. CAD,
coronary artery disease; DM, diabetes
mellitus; MERS-CoV, Middle East respi-
ratory syndrome coronavirus.
nses/by-nc-nd/4.0/).
FIG. 2. Percentage of patients (y-axis)
with specified score (x-axis) in those with
(solid line) and without (dashed line)
MERS-CoV infection. MERS-CoV, Middle
East respiratory syndrome coronavirus.
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with undifferentiated fever with or without respiratory symp-
toms or chest X-ray changes [21]. Differentiating patients with
MERS-CoV from other non–MERS-CoV patients has been a
challenge for the healthcare workers in Saudi Arabia. There are
no signs, symptoms, physical findings, specific laboratory or
radiologic findings that can help healthcare workers identify
MERS-CoV patients [17–19]. This was made clear from recent
MoH data, which showed that every year more than 50,000
patients suspected to be infected with MERS-CoV were tested
kingdomwide, with a yield of 0.7% positivity [22]. This calls for
regular review of MERS-CoV case definition and a reevaluation
of the visual triage scoring to ensure its accuracy and to avoid
clogging isolation rooms and exhausting MoH financial re-
sources by excessive testing of suspected MERS-CoV cases. In
addition, it is important to have healthcare organizations ready
to identify and isolate patients with suspected MERS-CoV. In a
recent study evaluating the readiness of hospitals in the United
States, 42 specific drills for patients with possible MERS-CoV
infection were conducted in New York City [23]. The drills
revealed variable identification of potentially infectious patients
and implementation of appropriate infection control measures
[23].
Rever-transcriptase PCR testing for MERS-CoV is the
reference standard test for MERS-CoV, and in the Kingdom of
Saudi Arabia, the MoH assigned five regional laboratories for
testing all samples (Makkah, Madinah, Jeddah, Riyadh and
Dammam). When samples are collected from the same city
where a laboratory is located, it takes an average of a full day for
the result, while samples from outside the city will take 1.5
days, and from one region to another, it will take 2 days. In the
setting of crowded EDs, limited numbers of isolation rooms and
the need to rapidly decide on contact tracing and intervention
for contacts of positive patients, this time frame is potentially
long.This is an open access articTo address this concern and to avoid a huge backlog of patients
in the ED, two strategies are needed. First, the case definition
needs to be revised after careful review of available data to the
MoH for 5 years. Second, we must invest in developing highly
sensitive and specific point-of-care testing in EDs and haemo-
dialysis units where the results will be available in 1 to 2 hours
[24–26]. Emerging diseases with regional and international im-
plications need to be addressed in a consultative format involving
all stakeholders locally, regionally and internationally.
The current study, conducted on a large number of patients,
showed that clinical scoring is not predictive of MERS infection.
Our results are robust and confirm that MERS cannot be
distinguished from other respiratory infections on the basis of
risk factors and clinical features. Thus, all patients with nonspe-
cific symptoms in a MERS-endemic area will have to be isolated
until MERS can be ruled out by PCR testing. This strategy has
important consequences in terms of public health, notably in
order to limit the transmission of MERS in the healthcare setting.
This is particularly relevant in countries where access to rapid
diagnosis is scarce. Meanwhile, until point-of-care MERS-CoV
testing is made available, triage of patients on the basis of the
current MoH triage score should be revised to a robust scoring
system.
The current study has few limitations. This is a retrospective
study, and thus the exact application of the findings on new cases
might not be generalizable. The study was performed in a MERS-
CoV referral centre, and the applicability of the findings to pa-
tients being seen in the ED therefore might not be accurate.
Thus, further refinement of the score is needed for better pre-
diction of MERS-CoV infection in patients seeking care in the ED.Conflict of interestNone declared.© 2018 The Author(s). Published by Elsevier Ltd, NMNI, 26, 49–52
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
52 New Microbes and New Infections, Volume 26 Number C, November 2018 NMNIReferences[1] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME,
Fouchier RAM. Isolation of a novel coronavirus from a man with
pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20.
[2] Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coro-
navirus: epidemiology and disease control measures. Infect Drug Resist
2014;7:281–7.
[3] Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA,
Cummings DAT, et al. Hospital outbreak of Middle East respiratory
syndrome coronavirus. N Engl J Med 2013;369:407–16.
[4] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-
Barrak A, et al. Epidemiological, demographic, and clinical character-
istics of 47 cases of Middle East respiratory syndrome coronavirus
disease from Saudi Arabia: a descriptive study. Lancet Infect Dis
2013;13:752–61.
[5] Penttinen PM, Kaasik-Aaslav K, Friaux A, Donachie A, Sudre B,
Amato-Gauci AJ, et al. Taking stock of the first 133 mers coronavirus
cases globally— is the epidemic changing? Euro Surveill 2013;18:
20596.
[6] Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H,
Aloraini MS, et al. 2014 MERS-CoV outbreak in Jeddah—a link to
health care facilities. N Engl J Med 2015;372:846–54.
[7] Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, HajOmar W,
et al. An observational, laboratory-based study of outbreaks of Middle
East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom
of Saudi Arabia, 2014. Clin Infect Dis 2015;60:369–77.
[8] Al-Tawfiq JA, Memish ZA. An update on Middle East respiratory
syndrome: 2 years later. Expert Rev Respir Med 2015;9:327–35.
[9] Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coro-
navirus: transmission and phylogenetic evolution. Trends Microbiol
2014;22:573–9.
[10] Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N,
et al. Novel coronavirus infections in Jordan, April 2012: epidemio-
logical findings from a retrospective investigation. East Mediterr Heal J
2013;19(Suppl. 1):S12–8.
[11] Kim Y, Lee S, Chu C, Choe S, Hong S, Shin Y. The characteristics of
Middle Eastern respiratory syndrome coronavirus transmission dy-
namics in South Korea. Osong Public Health Res Perspect 2016;7:
49–55.
[12] Seong MW, Kim SY, Corman VM, Kim TS, Cho SI, Kim MJ, et al.
Microevolution of outbreak-associated Middle East respiratory syn-
drome coronavirus, South Korea, 2015. Emerg Infect Dis 2016;22:
327–30.
[13] Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM.
Family cluster of Middle East respiratory syndrome coronavirus in-
fections. N Engl J Med 2013;368:2487–94.
[14] Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA,
Albarrak AM. A family cluster of Middle East respiratory syndrome© 2018 The Author(s). Published by Elsevier Ltd, NMNI, 26, 49–52
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licecoronavirus infections related to a likely unrecognized asymptomatic
or mild case. Int J Infect Dis 2013;17:e668–72.
[15] Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF,
et al. Community case clusters of Middle East respiratory syndrome
coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive
genomic study. Int J Infect Dis 2014;23:63–8.
[16] Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A,
et al. Middle East respiratory syndrome–coronavirus (MERS-CoV): a
case–control study of hospitalized patients. Clin Infect Dis 2014;59:
160–5.
[17] Mohd HA, Memish ZA, Alfaraj SH, McClish D, Altuwaijri T,
Alanazi MS, et al. Predictors of MERS-CoV infection: a large case
control study of patients presenting with ILI at a MERS-CoV referral
hospital in Saudi Arabia. Travel Med Infect Dis 2016;14:464–70.
[18] Garbati MA, Fagbo SF, Fang VJ, Skakni L, Joseph M, Wani TA, et al.
A comparative study of clinical presentation and risk factors for
adverse outcome in patients hospitalised with acute respiratory dis-
ease due to MERS coronavirus or other causes. PLoS One 2016;11,
e0165978.
[19] Command and Control Center Ministry of Health Kingdom of Saudi
Arabia Scientific Advisory Board. Infection prevention and control
guidelines for the Middle East respiratory syndrome coronavirus
(MERS-CoV) infection. 4th ed. 2017 Available at: http://www.moh.gov.
sa/endepts/Infection/Documents/Guidelines-for-MERS-CoV.PDF.
[20] Al-Tawfiq JA, Hinedi K, Abbasi S, Babiker M, Sunji A, Eltigani M. He-
matologic, hepatic, and renal function changes in hospitalized patients
with Middle East respiratory syndrome coronavirus. Int J Lab Hematol
2017;39:272–8.
[21] Singh K, Hsu LY, Villacian JS, Habib A, Fisher D, Tambyah PA. Severe
acute respiratory syndrome: lessons from Singapore. Emerg Infect Dis
2003;9:1294–8.
[22] Bin Saeed AA, Abedi GR, Alzahrani AG, Salameh I, Abdirizak F,
Alhakeem R, et al. Surveillance and testing for Middle East respiratory
syndrome coronavirus, Saudi Arabia, April 2015–February 2016.
Emerg Infect Dis 2017;23:682–5.
[23] Foote MMK, Styles TS, Quinn CL. Assessment of hospital emergency
department response to potentially infectious diseases using unan-
nounced mystery patient drills—New York City, 2016. MMWR Morb
Mortal Wkly Rep 2017;66:945–9.
[24] Huh HJ, Kim JY, Kwon HJ, Yun SA, Lee MK, Ki CS, et al. Performance
evaluation of the PowerChek MERS (upE & ORF1a) real-time PCR kit
for the detection of Middle East respiratory syndrome coronavirus
RNA. Ann Lab Med 2017;37:494–8.
[25] Lee SH, Baek YH, Kim YH, Choi YK, Song MS, Ahn JY. One-pot
reverse transcriptional loop-mediated isothermal amplification (RT-
LAMP) for cetecting MERS-CoV. Front Microbiol 2017:2166.
[26] Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respi-
ratory syndrome coronavirus (MERS-CoV) outbreak in South Korea,
2015: epidemiology, characteristics and public health implications.
J Hosp Infect 2017;95:207–13.nses/by-nc-nd/4.0/).
